ArticleChinese medical journal2026
Conversion surgery after immunotherapy and chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology: A retrospective cohort study.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of conversion therapy for gastric cancer with peritoneal metastasis (P1) and/or positive peritoneal lavage cytology (CY1) treated with immunotherapy remains unclear. This study aimed to clarify clinical outcomes in this setting.
methodsIn this retrospective, single-institution cohort study, 144 patients with P1 and/or CY1 confirmed by staging laparoscopy at initial diagnosis received first-line immunotherapy with chemotherapy and/or trastuzumab between November 2019 and March 2024. Patients were divided into a conversion therapy group and a palliative therapy group.
resultsOf 144 patients, 75 showed a clinical response and underwent second-look laparoscopy. Negative peritoneal metastasis and cytology were confirmed in 36 patients, all of whom underwent conversion surgery. Compared with the palliative group, the conversion group had significantly longer median progression-free survival (22.9 vs . 5.8 months; P <0.001) and overall survival (33.4 vs . 12.3 months; P <0.001). Among those who had surgery, 27 patients (75.0%, 27/36) achieved R0 resection (complete resection with no residual tumor). Patients with peritoneal cancer index ≤2 had a significantly longer median overall survival than those with peritoneal cancer index >2 (not reached vs . 28.5 months; P <0.006). No serious treatment-related adverse events led to treatment discontinuation or death.
conclusionsConversion surgery following immunochemotherapy provided a significant survival benefit for gastric cancer patients with P1 and/or CY1. When immunochemotherapy is effective, active staging laparoscopy should be performed to assess surgical feasibility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.